Consider Hims & Hers (HIMS) as the premier sector leader for high-growth exposure to the telehealth megatrend, driven by its dominant scale and projected revenue growth of 34% to 40%.

Alternatively, view LifeMD (LFMD) as a high-risk, deep-value turnaround play or speculative acquisition target given its dirt-cheap price-to-sales multiple of 0.6 and built-out insurance-reimbursement infrastructure.

Investors in LFMD should closely monitor management's ability to achieve positive EBITDA by the end of the year without causing further deceleration from its modest 8% projected 2026 revenue growth.

Evaluate LFMD's unique insurance-accepting model as a potential defensive moat against pure-play competitors, especially regarding future Medicare tailwinds for GLP-1 medications.

Track upcoming guidance updates for HIMS following recent acquisitions like Eucalyptus to ensure the company continues outpacing smaller telehealth peers.

LifeMD (LFMD)

• The company is experiencing slowing revenue growth, projected at 8% for 2026, compared to high-growth competitors like Hims & Hers (HIMS) which are growing at over 30%.
• Valuation is considered dirt cheap with a price-to-sales ratio of 0.6 and an enterprise value to gross profit that is roughly on par with Hims & Hers, driven by a strong gross margin of 87%.
• EBITDA is currently negative following the sale of their software business, WorkSimply, though management aims to reach positive EBITDA by the end of the year by shifting marketing strategy.
• LifeMD differentiates itself by accepting insurance, giving them access to commercially insured lives, Medicare Advantage, and Medicare fee-for-services beneficiaries, including potential tailwinds from Medicare covering GLP-1 medications.
• The active patient count sits at roughly 356,000, which is significantly smaller than Hims & Hers, putting them at a disadvantage for training and running AI recommender systems efficiently.
• Marketing strategy is shifting away from purely performance-based paid media, and the company operates multiple sub-brands like Rex MD (men's health/ED) and Optimal Human Health MD (women's health/menopause) alongside the main LifeMD brand.
• The company has built a vertically integrated platform including a direct-to-patient pharmacy, a compounding facility, lab partnerships (such as Quest Diagnostics), and urgent care services.
• Due to its small market capitalization of around $140 million and built-out insurance-processing infrastructure, the company could potentially serve as an acquisition target for a legacy healthcare player, big pharma, or a direct-to-consumer initiative like Eli Lilly's LillyDirect.

Takeaways

• Consider LifeMD (LFMD) as a high-risk, deep-value turnaround play or speculative acquisition target due to its extremely low price-to-sales multiple of 0.6 and established insurance-reimbursement infrastructure.
• Monitor management's ability to achieve positive EBITDA by the end of the year through reduced or altered marketing spend without causing further deceleration in revenue growth.
• Weigh the slower growth velocity associated with accepting insurance against the built-in moat of catering to patients who prefer utilizing their health insurance benefits or Medicare.

Hims & Hers Health (HIMS)

• Positioned as the clear "winner-take-most" leader in the telehealth and digital pharmacy space, boasting roughly 2.6 to 2.9 million customers (roughly 10 times the customer base of LifeMD).
• Projected forward revenue growth is significantly higher than competitors, ranging between 34% to 40%, bolstered by recent expansions like the Eucalyptus acquisition and aggressive pricing strategies such as $39 consultation fees for GLP-1 treatments.
• Benefits from a much larger customer dataset, allowing for more efficient AI implementation and cross-selling across multiple subscription categories.
• Maintains a unified brand strategy (having shut down secondary brands like Apostrophe in the UK and rebranding Canadian acquisitions to Hims), which drives marketing efficiency compared to competitors with fragmented brand portfolios.
• Marketing spend is viewed as a high-ROI customer acquisition investment rather than a dead expense, successfully fueling long-term subscription retention and lifetime value.

Takeaways

• Treat Hims & Hers (HIMS) as the preferred sector leader for investors seeking high-growth exposure to the digital doctor and telehealth megatrend, supported by scale advantages and strong brand consolidation.
• Watch for upcoming guidance updates following recent acquisitions and customer milestone announcements to gauge whether the company continues to outpace smaller telehealth peers.